Adalimumab-Aacf
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study.
Journal: Advances in rheumatology (London, England)
Published: March 07, 2025
Comparing adalimumab biosimilars in the clinical practice of psoriatic patients.
Journal: Italian journal of dermatology and venereology
Published: February 03, 2025
Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars.
Journal: Advances in pharmacological and pharmaceutical sciences
Published: December 09, 2024
Navigating adalimumab biosimilars: an expert opinion.
Journal: Journal of comparative effectiveness research
Published: October 19, 2023
Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
Published: October 11, 2023
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience.
Journal: The Journal of dermatological treatment
Published: June 05, 2023
Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers.
Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers.
Journal: International journal of pharmaceutics: X
Published: May 14, 2023
Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
Journal: Expert opinion on biological therapy
Published: April 18, 2023
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
Journal: Expert opinion on biological therapy
Published: April 25, 2022
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.
Journal: Dermatology and therapy
Published: February 28, 2022
Expanded Table: Some biologic drugs and JAK inhibitors for rheumatoid arthritis.
Journal: The Medical letter on drugs and therapeutics
Published: January 27, 2022
Ozanimod (Zeposia) for ulcerative colitis.
Journal: The Medical letter on drugs and therapeutics
Published: September 22, 2021
Last Updated: 04/28/2026